The taxanes: An update

Lancet

Volumn 355, Issue 9210, 2000, Pages 1176-1178

  Crown, John ^a   O'Leary, Michael ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; DIARRHEA; FATIGUE; LUNG CARCINOMA; MYALGIA; NEUROPATHY; OVARY CARCINOMA; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034177397     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02074-2     Document Type: Review

References (43)

1. Eisenhauer A.E., ten Bokkel Huinink W.W.et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer. high-dose versus low-dose and long versus short infusion J Clin Oncol. 12:1994;2654-2666.
2. ten Bokkel Huinink W., Gore M., Carmichael J.et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 15:1997;2183-2193.
3. Muggia F.M., Braly P.S., Brady M.F.et al. Phase III randomised study of cisplatin versus paclitaxel versus ciplatin and paclitaxel in patients with suboptimul stage III or IV ovarian cancer. a Gynecologic Oncology Group Study J Clin Oncol. 18:2000;106.
4. Reichman B.S., Seidman A.D., Crown J.P.et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 11:1993;1943-1951.
5. Hudis C.A., Seidman A.D., Crown J.P.et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 14:1996;58-65.
6. Smith R.E., Brown A.M., Mamounas E.et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol J Clin Oncol. 17:1999;3403-3411.
7. Holmes F.A., Valero V., Buzdar A.U.et al. Final results: randomized phase III trial of paclitaxel by 3 hour versus 96 hour infusion in patients (pts) with metastatic breast cancer (MBc): the long and the short of it. Proc ASCO. 17:1998;110a. (abstr 426).
8. Peretz T., Sulket A., Challet R.et al. A multi-center randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer. 31A:1995;s75. (abstr 345).
9. Nabholtz J.M., Gelmon K., Bontenbal M.et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 14:1996;1858-1867.
10. Winer E., Berry D., Duggan D.et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: results from CALGB 9342. Proc ASCO. 17:1998;101a. (abstr 388).
11. Crown J. Phase III randomized trials of docetaxel in patients with metastatic breast cancer. Semin Oncol. 26:1999;33-38. (suppl 8).
12. Buzdar A.U., Singletary E., Theriault R.L.et al. Prospective evaluation of paclitaxel versus combination therapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 17:1999;3412-3417.
13. Bishop J.F., Dewar J., Toner G.C.et al. Paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 17:1999;2355.
14. Nabholtz J.M., Senn H.J., Bezwoda w.r.et al. Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 17:1999;1413.
15. Monnier A., Bonneterre J., Roche H.et al. Phase III study: Taxotere (TXT) versus 5-Fluorouracil + navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy (CT) (preliminary results). Ann Oncol. 9:1998;12. (abstr 58)(suppl 4).
16. Roszkowski K. Taxotere (TXT) versus best supportive care (BSC) in chemonaive patients with unresectable non-small cell lung cancer (NSCLC): final results of the phase III study. Eur J Cancer. 35:1999;s246. (abstr 976)(suppl 4).
17. Thatcher N., Ranson M., Anderson H.et al. Phase III study of paclitaxel (taxol) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC). Ann Oncol. 9:1998;1. (suppl 4).
18. Shepherd R., Ramlau K., Mattson L.et al. Randomized study of taxotere (TAX) versus best support care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Proc ASCO. 18:1999;463a. (abstr 1784).
19. Dancey J., Shepherd F., Ramlau K.et al. Quality of life (QOL) assessment in a randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy. Proc ASCO. 18:1999;491a. (abstr 1896).
20. 2 vs vinorelbine/ifosfamide for non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy (PBC). Proc ASCO. 18:1999;460c. (abstr 1776).
21. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
22. Stuart G., Bertelsen K., Mangioni C.et al. Updated analysis shows a highly significantly improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC GCCGC, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc ASCO. 17:1998;361a. (abstr 1394).
23. Ozols R.F., Bundy B.N., Fowler J.et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Trial (GOG 158). Proc ASCO. 18:1999;356a. (abstr 1373).
24. Harper P. A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Proc ASCO. 18:1999;356c. (abstr 1375).
25. Gianni L., Munzone E., Capri G.et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study J Clin Oncol. 13:1995;2688-2699.
26. Sledge G.W. Jr., Neuberg D., Ingle J., Martino S., Wood W. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin+paclitaxel (A+T) as first-line therapy for matastatic breast cancer (MBC): an intergroup trial. Proc ASCO. 16:1997;1a. (abstr 2).
27. Harvey J., Cantrell J., Campbell M.et al. Mitoxantrone+paclitaxel (NT) versus paclitaxel (T) alone for metastatic breast cancer (MBC). Proc ASCO. 16:1997;601.
28. Pluzzanska A., Jassem J., Jelic S.et al. Randomized open-label phase III multicenter trial comparing TAXOL/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophophamide (FAC) as a first line treatment for patients with metastatic breast cancer. Eur J Cancer. 35:1999;s314. (abstr 1260)(suppl 4).
29. Nabholtz J.M., Falkson G.D., Campos J.et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc ASCO. 18:1999;127a. (abstr 485).
30. Wasserheit C., Frazein A., Oratz R.et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer. an active regimen with limiting neurotoxicity J Clin Oncol. 14:1996;1993-1999.
31. Henderson I.C., Berry D., Demetri G.et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc ASCO. 17:1998;101a. (abstr 390A).
32. Pegram M., Hsu S., Lewis G.et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18:1999;2241-2251.
33. Baselga J.K., Norton L., Albanell J., Kim Y.M., Mendesohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
34. Norton L., Slamon D., Leyland-Jones B.et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc ASCO. 18:1999;127a. (abstr 483).
35. Kim K., Bonomi P.D., Kugler J., Johnson D.H. Two year survival and prognostic factors for overall survival in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group experience. Proc ASCO. 17:1998;461a. (abstr 1773).
36. Gatzemeier U., von Pawel J., Gottfried M.et al. Phase III comparative study of high-dose cisplatin (HD-Cis) versus a combination of paclitaxel (tax) and cisplatin (cis) in patients with advanced non-small cell lung cancer. Proc ASCO. 17:1998;454a. (abstr 1748).
37. Giaccone G., Splinter T.A., Debruyne C.et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 16:1998;2133-2141.
38. Belani C.P., Natale R.B., Lee J.S.et al. Randomised phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc ASCO. 17:1998;455c. (abstr 1751).
39. Kelly K., Crowley J., Bunn P.A., Livingston R.B., Gandara D.R. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) Trial. Proc ASCO. 18:1999;461a. (abstr 1777).
40. Georgoulias V., Papadakis E., Alexopoulos A.et al. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial. Proc ASCO. 18:1999;461a. (abstr 1778).
41. Petrylak D.P., Macarthur R.B., O'Connor J.et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 17:1999;958-967.
42. McCaffrey J.A., Hilton S., Mazumdar M., Sadan S., Kelly W.K., Scher H.I., Bajorin D.F. Phase III trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 15:1997;1853-1857.
43. Crown J., Chan K.M., O'Leary M.et al. Feasibility of an accelerated multi-cycle high-dose chemotherapy regimen including high-dose thiotepa for patients (pts) with poor-risk ovarian cancer (OC). Eur J Cancer. 35:1999;s232. (suppl 4).